Red blood cells and thrombin generation in sickle cell disease.
The prothrombotic nature of sickle cell disease (SCD) is evidenced by the chronically elevated levels of almost all coagulation activation biomarkers, and an increased incidence of certain thrombotic events, including venous thromboembolism. Numerous studies have attempted to define the extent and elucidate the mechanism of the observed increase in thrombin generation in SCD patients in vivo. In general, these studies were performed using thrombin generation assays in platelet poor or platelet rich plasma and showed little difference in endogenous thrombin potential between the SCD cohort and healthy matched controls. In SCD, erythrocytes and monocytes have been demonstrated to exhibit procoagulant characteristics. Thus, the absence of these cellular components in standard thrombin generation assays may fail to reflect global hypercoagulability in the whole blood of patients with SCD. We were therefore surprised to see no difference in net thrombin generation in tissue factor-initiated initiated clotting of whole blood from patients with SCD. However, we are continuing to reconcile these seemingly disparate observations by slight modifications of the whole blood model that include alternative coagulation triggers and a re-examination of the net thrombin generation when the protein/protein S system is simultaneously interrogated.
Division of Hematology/Oncology, Department of Medicine, University of NC at Chapel Hill, USA.
Matthew F
MF
Whelihan
Division of Hematology/Oncology, Department of Medicine, University of NC at Chapel Hill, USA.
Ming Y
MY
Lim
Division of Hematology/Oncology, Department of Medicine, University of NC at Chapel Hill, USA. Electronic address: nigel_key@med.unc.edu.
Nigel S
NS
Key
D000755:Anemia, Sickle Cell / Q000097:blood* / Q000378:metabolism / Q000473:pathology; D001777:Blood Coagulation; D004912:Erythrocytes / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D013917:Thrombin / Q000378:metabolism*
D013917:Thrombin